NERV Minerva Neurosciences, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

NERV [NASD]

Minerva Neurosciences, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.70	Insider Own	0.10%	Shs Outstand	39.48M	Perf Week	-0.90%
Market Cap	132.29M	Forward P/E	-	EPS next Y	-0.81	Insider Trans	-3.22%	Shs Float	35.75M	Perf Month	8.22%
Income	-26.50M	PEG	-	EPS next Q	-0.23	Inst Own	68.00%	Short Float	9.91%	Perf Quarter	-9.37%
Sales	41.20M	P/S	3.21	EPS this Y	-43.10%	Inst Trans	0.37%	Short Ratio	4.80	Perf Half Y	-62.36%
Book/sh	1.44	P/B	2.28	EPS next Y	-8000.00%	ROA	-32.80%	Target Price	-	Perf Year	-20.34%
Cash/sh	0.88	P/C	3.75	EPS next 5Y	-	ROE	-66.70%	52W Range	1.81 - 15.22	Perf YTD	-53.73%
Dividend	-	P/FCF	-	EPS past 5Y	16.20%	ROI	-	52W High	-78.38%	Beta	1.50
Dividend %	-	Quick Ratio	4.80	Sales past 5Y	-	Gross Margin	-	52W Low	81.77%	ATR	0.17
Employees	13	Current Ratio	4.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	49.97	Volatility	4.76% 5.17%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	329.30%	Profit Margin	-64.40%	Rel Volume	0.26	Prev Close	3.21
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 03 BMO	Payout	-	Avg Volume	737.18K	Price	3.29
Recom	2.00	SMA20	-0.47%	SMA50	1.08%	SMA200	-43.37%	Volume	190,344	Change	2.49%

Jun-08-20

Reiterated

H.C. Wainwright

Buy

$20 → $10

May-14-20

Initiated

BTIG Research

Buy

$23

Oct-02-19

Reiterated

Chardan Capital Markets

Buy

$17

Sep-25-19

Initiated

Chardan Capital Markets

Buy

$17

Sep-18-19

Initiated

William Blair

Outperform

May-31-19

Initiated

H.C. Wainwright

Buy

Sep-01-17

Initiated

Citigroup

Buy

$11

Mar-06-17

Resumed

Jefferies

Buy

$17

May-12-16

Resumed

Jefferies

Buy

Oct-05-20 03:00PM	We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely Simply Wall St. +7.96%
Sep-14-20 10:20AM	These 3 Penny Stocks Could Double (Or More), Says BTIG TipRanks +18.12%
Sep-09-20 08:30AM	Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire
Sep-02-20 08:30AM	Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference GlobeNewswire
Aug-13-20 08:00AM	Minerva Neurosciences to Present at JMP Securities CNS Forum GlobeNewswire
Aug-05-20 09:30AM	How Much Did Minerva Neurosciences'(NASDAQ:NERV) Shareholders Earn From Share Price Movements Over The Last Three Years? Simply Wall St.
Aug-03-20 07:01PM	Minerva Neurosciences (NERV) Q2 2020 Earnings Call Transcript Motley Fool +5.88%
07:30AM	Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates GlobeNewswire
Jul-27-20 08:00AM	Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020 GlobeNewswire
Jul-01-20 08:00AM	Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202) GlobeNewswire
Jun-27-20 03:17PM	Hedge Fund Sentiment Is Stagnant On Minerva Neurosciences, Inc (NERV) Insider Monkey
Jun-22-20 08:47AM	Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't? Zacks
Jun-05-20 09:05AM	Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session Zacks -7.98%
Jun-02-20 09:00AM	How Minerva Neurosciences (NERV) Stock Stands Out in a Strong Industry Zacks -7.36%
Jun-01-20 02:15PM	Why Minerva Neurosciences Is Heading Higher Today Motley Fool +13.48%
08:00AM	REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia GlobeNewswire
May-31-20 07:50AM	Minerva Shares Tank 72% As Schizophrenia Drug Misses Trial Goals SmarterAnalyst
May-29-20 04:50PM	Here's Why Minerva Neurosciences Collapsed Today Motley Fool -72.46%
11:48AM	Minerva Schizophrenia-Drug Trial Misses Key Endpoints TheStreet.com
10:31AM	Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne Zacks
10:15AM	Minerva Neurosciences' stock plummets after schizophrenia treatment disappoints in phase 3 study MarketWatch
09:20AM	Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia GlobeNewswire
May-27-20 09:40AM	Small Drug Industry Prospects Bright Amid Coronavirus Gloom Zacks
May-26-20 11:41AM	Top Ranked Momentum Stocks to Buy for May 26th Zacks
10:43AM	Baker Brothers Snap Up These 3 Small-Cap Biotech Stocks TipRanks
May-25-20 06:41PM	Edited Transcript of NERV earnings conference call or presentation 4-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-11-20 09:52AM	Top Ranked Momentum Stocks to Buy for May 11th Zacks +9.23%
08:41AM	Are Options Traders Betting on a Big Move in Minerva Neurosciences (NERV) Stock? Zacks
May-08-20 07:55AM	New Strong Buy Stocks for May 8th Zacks +8.70%
May-04-20 06:30PM	Minerva Neurosciences Inc (NERV) Q1 2020 Earnings Call Transcript Motley Fool
07:30AM	Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates GlobeNewswire
Apr-27-20 08:30AM	Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020 GlobeNewswire +6.59%
Apr-20-20 01:40PM	Minerva Neurosciences, Inc. (NASDAQ:NERV): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Mar-28-20 02:49AM	Edited Transcript of NERV earnings conference call or presentation 9-Mar-20 12:30pm GMT Thomson Reuters StreetEvents
Mar-24-20 08:30AM	MINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA GlobeNewswire
Mar-19-20 10:50AM	Are Options Traders Betting on a Big Move in Minerva Neurosciences (NERV) Stock? Zacks +6.35%
Mar-12-20 03:15PM	MINERVA NEUROSCIENCES UPDATES MARKET ON SHARE PRICE DROP AND TRADING HALT GlobeNewswire -13.99%
Mar-09-20 07:30AM	Minerva Neurosciences Reports Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates GlobeNewswire -14.59%
06:30AM	Minerva Neurosciences, Inc. to Host Earnings Call ACCESSWIRE
Mar-02-20 08:30AM	Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020 GlobeNewswire
Feb-28-20 08:30AM	Minerva Neurosciences to Host Key Opinion Leader Meeting on Avolition, the Most Central Domain for the Successful Treatment of Negative Symptoms in Schizophrenia GlobeNewswire
Feb-17-20 11:15AM	Who Has Been Buying Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares? Simply Wall St.
Feb-05-20 08:00AM	Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia GlobeNewswire +5.18%
Jan-06-20 08:00AM	Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia GlobeNewswire
Dec-24-19 07:06AM	Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch +9.42%
Dec-19-19 03:07PM	Minerva shares fall on failed depression drug trial MarketWatch -17.85%
09:35AM	Minerva Neurosciences Shelves Depression Drug Study After Failed Mid-Stage Trial Benzinga
07:52AM	The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
Dec-18-19 04:05PM	Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder GlobeNewswire
Dec-17-19 07:47PM	Hedge Funds Are Buying Minerva Neurosciences, Inc (NERV) Insider Monkey -5.11%
08:29AM	Here's Why We're Not Too Worried About Minerva Neurosciences's (NASDAQ:NERV) Cash Burn Situation Simply Wall St.
Dec-04-19 04:05PM	SI-BONE Names Jeryl (Jeri) Hilleman to Board of Directors GlobeNewswire
Nov-21-19 12:21AM	Edited Transcript of NERV earnings conference call or presentation 4-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-14-19 08:30AM	Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019 GlobeNewswire
Nov-11-19 12:10AM	Minerva Neurosciences, Inc (NERV): Are Hedge Funds Right About This Stock? Insider Monkey
Nov-04-19 07:30AM	Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates GlobeNewswire
Oct-28-19 08:30AM	Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019 GlobeNewswire
Oct-18-19 09:37AM	Does The Minerva Neurosciences, Inc. (NASDAQ:NERV) Share Price Tend To Follow The Market? Simply Wall St.
Oct-02-19 08:47AM	Company News For Oct 2, 2019 Zacks -12.96%
Oct-01-19 04:43PM	Investor Alert: Kaplan Fox Investigates Minerva Neurosciences, Inc. (NASDAQ: NERV) PR Newswire -26.32%
09:23AM	Stocks - U.S. Steel Slumps, Spotify, Tesla Rise Premarket Investing.com
08:49AM	Minerva's stock plunges to lead all premarket losers after cyber-attack delays enrollment in a phase 3 trial MarketWatch
07:30AM	Minerva Neurosciences Announces Update for Three Clinical Trials GlobeNewswire
Sep-26-19 04:10PM	Minerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8:30 AM ET GlobeNewswire
Sep-24-19 09:00AM	Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone GlobeNewswire
Sep-23-19 11:46AM	Zacks.com featured highlights include: ACM Research, GAIN Capital, Cutera, Columbus McKinnon and Minerva Zacks
Sep-20-19 09:10AM	Moving Average Crossover Alert: Minerva Neurosciences Zacks
Sep-19-19 09:38AM	5 Stocks to Buy on New Analyst Coverage Zacks
Sep-03-19 10:53AM	What Kind Of Shareholder Appears On The Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Shareholder Register? Simply Wall St.
Aug-09-19 03:08AM	Edited Transcript of NERV earnings conference call or presentation 5-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-05-19 03:59PM	Minerva Neurosciences, Inc. (NERV) Q2 2019 Earnings Call Transcript Motley Fool +8.06%
07:30AM	Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates GlobeNewswire
Jul-29-19 08:00AM	Minerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019 GlobeNewswire
Jul-04-19 11:36AM	Did Minerva Neurosciences, Inc. (NASDAQ:NERV) Insiders Buy Up More Shares? Simply Wall St.
Jun-28-19 03:19PM	Is Minerva Neurosciences, Inc (NERV) A Good Stock To Buy? Insider Monkey
Jun-24-19 11:00AM	Minerva Spikes Higher After Novel Insomnia Drug Aces Mid-Stage Trial Benzinga +40.19%
08:12AM	UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals MarketWatch
07:30AM	Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia GlobeNewswire
Jun-23-19 05:30PM	Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant GlobeNewswire
Jun-12-19 08:30AM	Minerva Neurosciences to Present at JMP Securities Life Sciences Conference GlobeNewswire
May-29-19 08:30AM	Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019 GlobeNewswire
May-13-19 11:01AM	Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug Benzinga
08:15AM	Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs GlobeNewswire
May-10-19 09:29AM	Edited Transcript of NERV earnings conference call or presentation 6-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-07-19 02:06PM	Calculating The Fair Value Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Simply Wall St.
May-06-19 12:00PM	Minerva Neurosciences, Inc. (NERV) Q1 2019 Earnings Call Transcript Motley Fool -5.15%
07:35AM	Minerva Neurosciences: 1Q Earnings Snapshot Associated Press
07:30AM	Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates GlobeNewswire
Apr-29-19 08:30AM	Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019 GlobeNewswire
Apr-11-19 08:30AM	Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia GlobeNewswire
Mar-18-19 11:41AM	Edited Transcript of NERV earnings conference call or presentation 12-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
08:30AM	Minerva Neurosciences to Host Webcast Event on Schizophrenia GlobeNewswire
Mar-12-19 12:53PM	Minerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:46AM	Minerva Neurosciences: 4Q Earnings Snapshot Associated Press
07:30AM	Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates GlobeNewswire
Mar-05-19 08:00AM	Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019 GlobeNewswire
Feb-05-19 08:30AM	Factors of Influence in 2019, Key Indicators and Opportunity within Wright Medical Group N.V, MSA Safety Incorporporated, Minerva Neurosciences, OSI, Argan, and Approach Resources New Research Emphasizes Economic Growth GlobeNewswire
Dec-20-18 11:32AM	How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own? Simply Wall St.
Nov-28-18 08:00AM	Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain GlobeNewswire
Nov-21-18 08:30AM	Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018 GlobeNewswire

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VAN HEEK G JAN	Director	Sep 10	Buy	2.97	7,000	20,790	20,333	Sep 11 05:13 PM
Ahlholm Frederick W	SVP, Chief Accounting Officer	May 26	Sale	15.00	8,339	125,085	6,884	May 27 04:43 PM
Race Geoff	EVP, CFO & CBO	Dec 17	Sale	7.10	5,826	41,365	205,044	Dec 17 04:48 PM
Luthringer Remy	CEO	Dec 17	Sale	7.10	2,412	17,125	49,040	Dec 17 04:46 PM
Ahlholm Frederick W	SVP, Chief Accounting Officer	Dec 17	Sale	7.10	1,557	11,055	15,223	Dec 17 04:45 PM
Reilly Joseph H.	SVP & Chief Operating Officer	Dec 17	Sale	7.10	2,724	19,340	26,225	Dec 17 04:44 PM
Russell Richard E.	President	Dec 12	Sale	7.42	3,113	23,098	33,770	Dec 13 04:07 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience